Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products January 2024

Download the Draft Guidance Document Read the Federal Register Notice
Draft Level 1 Guidance

Not for implementation. Contains non-binding recommendations.

This guidance is being distributed for comment purposes only.

Docket Number:
FDA-2016-D-3561
Issued by:
Guidance Issuing Office
Oncology Center of Excellence
Center for Biologics Evaluation and Research
Center for Devices and Radiological Health
Center for Drug Evaluation and Research
Office of the Commissioner, Office of Minority Health and Health Equity
Office of the Commissioner, Office of Women's Health
Office of the Commissioner, Office of Clinical Policy and Programs
Office of the Commissioner, Office of Clinical Policy and Programs, Office of Pediatric Therapeutics

The purpose of this guidance is to provide FDA’s expectations for, and recommendations on, use of a standardized approach for collecting and reporting race and ethnicity data in submissions including information collected and reported from clinical studies and clinical trials for FDA-regulated medical products.  Using standard terminology for race and ethnicity helps ensure that data are collected and reported consistently in submissions to FDA.  This draft guidance revises the final guidance for industry and FDA staff entitled “Collection of Race and Ethnicity Data in Clinical Trials” issued on October 26, 2016.

 
Back to Top